BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ipilimumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ipilimumab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06712927-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06712927)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Trial of Relatlimab\, 
 Nivolumab\, and Ipilimumab in Patients With Asymptomatic and Symptomatic M
 elanoma Brain Metastases\nEstimated primary completion: November 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06712927
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03223155-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT03223155)
DESCRIPTION:Ipilimumab\, phase 1.\nStudy: Concurrent or Sequential Immunoth
 erapy and Radiation Therapy in Patients With Metastatic Lung Cancer\nEstim
 ated primary completion: December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03223155
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04283890-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT04283890)
DESCRIPTION:Ipilimumab\, phase 1/2\, Melanoma.\nStudy: PHP and Immunotherap
 y in Metastasized UM\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04283890
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03340129-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03340129)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Anti-PD 1 Brain Collab
 oration + Radiotherapy Extension (ABC-X Study)\nEstimated primary completi
 on: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ip
 ilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03340129
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05647265-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05647265)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Testing the Addition of Immunothe
 rapy Before Surgery for Patients With Sarcomatoid Mesothelioma\nEstimated 
 primary completion: 15 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05647265
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04413123-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20261220
DTEND;VALUE=DATE:20261221
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT04413123)
DESCRIPTION:Ipilimumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Cabozantin
 ib In Combo With NIVO + IPI In Advanced NCCRCC\nEstimated primary completi
 on: 20 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04413123
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04606316-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT04606316)
DESCRIPTION:Ipilimumab\, phase 1.\nStudy: Surgical Nivolumab And Ipilimumab
  For Recurrent GBM\nEstimated primary completion: 30 December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04606316
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03333616-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03333616)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Nivolumab Combined With Ipilimuma
 b for Patients With Advanced Rare Genitourinary Tumors\nEstimated primary 
 completion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT03333616
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03776487-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03776487)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Nivolumab\, Ipilimumab and Chemor
 adiation in Treating Patients With Resectable Gastric Cancer\nEstimated pr
 imary completion: 30 December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03776487
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06324240-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT06324240)
DESCRIPTION:Ipilimumab\, phase 1.\nStudy: Personalized Vaccine Immunotherap
 y in Combination With Checkpoint Inhibitor for Treatment of Triple Negativ
 e Breast Cancer\nEstimated primary completion: 31 December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06324240
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02210117-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT02210117)
DESCRIPTION:Ipilimumab\, phase 1\, Renal Cell Carcinoma.\nStudy: Nivolumab 
 With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patie
 nts With Metastatic Kidney Cancer That Can Be Removed by Surgery\nEstimate
 d primary completion: 31 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT02210117
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04388852-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT04388852)
DESCRIPTION:Ipilimumab\, phase 1\, Urothelial Carcinoma.\nStudy: DS3201 and
  Ipilimumab for the Treatment of Metastatic Prostate\, Urothelial and Rena
 l Cell Cancers\nEstimated primary completion: 31 December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04388852
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05597800-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05597800)
DESCRIPTION:Ipilimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Nivo
 lumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients W
 ith HIV\, HBV\, HCV and Long Covid Syndrome\nEstimated primary completion:
  31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ip
 ilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05597800
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05492123-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05492123)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Nivolumab-ipilimumab and Chemorad
 iation for Cervical Cancer\nEstimated primary completion: 31 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05492123
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155317-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07155317)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Time-of-Day Specified 
 Immunotherapy for Advanced Melanoma\, The TIME Trial\nEstimated primary co
 mpletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07155317
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03297606-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03297606)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Canadian Profiling and Targeted A
 gent Utilization Trial (CAPTUR)\nEstimated primary completion: 31 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0329760
 6
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03520491-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03520491)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: A Study to Test the Safety of Imm
 unotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Blad
 der Cancer Patients Who Are Not Suitable for Chemotherapy\nEstimated prima
 ry completion: January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03520491
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03104439-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03104439)
DESCRIPTION:Ipilimumab\, phase 2\, Colorectal Cancer.\nStudy: Nivolumab and
  Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancr
 eatic Cancer\nEstimated primary completion: January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03104439
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134842-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT07134842)
DESCRIPTION:Ipilimumab\, phase 1.\nStudy: A Study Assessing if it is Safe a
 nd Possible to Treat Brain Cancer Patients With Immunotherapy Before They 
 Receive the Standard Treatment.\nEstimated primary completion: 1 January 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07134842
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05584670-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270120
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT05584670)
DESCRIPTION:Ipilimumab\, phase 1/2.\nStudy: A First-in-human\, Dose Escalat
 ion and Dose Expansion Study of SAR445877 in Adult Participants With Advan
 ced Solid Tumors\nEstimated primary completion: 19 January 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05584670
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06250335-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270123
DTEND;VALUE=DATE:20270124
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06250335)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Impact of a Prebiotic 
 Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combi
 nation Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patient
 s\nEstimated primary completion: 23 January 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06250335
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05176483-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT05176483)
DESCRIPTION:Ipilimumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Stud
 y of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in 
 Participants With Solid Tumors\nEstimated primary completion: 31 January 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05176483
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03816358-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT03816358)
DESCRIPTION:Ipilimumab\, phase 1.\nStudy: Testing the Combination of Anetum
 ab Ravtansine With Either Nivolumab\, Nivolumab and Ipilimumab\, or Gemcit
 abine and Nivolumab in Advanced Pancreatic Cancer\nEstimated primary compl
 etion: 31 January 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03816358
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04079166-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT04079166)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: SCIB1 and iSCIB1+ in M
 elanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrol
 izumab (The SCOPE Study)\nEstimated primary completion: 31 January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04079166
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04462406-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT04462406)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Using Biomarkers to He
 lp Guide Safe Immunotherapy Discontinuation in Patients With Unresectable 
 Stage IIIB-IV Melanoma\, The PET-Stop Trial\nEstimated primary completion:
  31 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipi
 limumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04462406
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04472767-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT04472767)
DESCRIPTION:Ipilimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Caboza
 ntinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepato
 cellular Carcinoma\nEstimated primary completion: 31 January 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04472767
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05407441-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT05407441)
DESCRIPTION:Ipilimumab\, phase 1/2.\nStudy: Tazemetostat+Nivo/Ipi in INI1-N
 eg/SMARCA4-Def Tumors\nEstimated primary completion: 1 February 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05407441
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04551430-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT04551430)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Cabozantinib Combined With PD-1 a
 nd CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma\nEstimated primary 
 completion: 1 February 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04551430
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06946797-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06946797)
DESCRIPTION:Ipilimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combinati
 on With Intravenous Ipilimumab and Chemotherapy in Participants With Previ
 ously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
 \nEstimated primary completion: 5 February 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06946797
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Ipilimumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Sa
 fety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Glio
 blastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 2
 8 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipil
 imumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06047379
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03866382-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03866382)
DESCRIPTION:Ipilimumab\, phase 2\, Urothelial Carcinoma.\nStudy: Testing th
 e Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With
  One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumor
 s\nEstimated primary completion: 28 February 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT03866382
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07422753-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07422753)
DESCRIPTION:Ipilimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Pros
 pective\, Randomized Study of TACE Combined With Sintilimab\, Bevacizumab\
 , and Ipilimumab N01 Treating Advanced HCC\nEstimated primary completion: 
 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 422753
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05141721-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Ipilimumab: Phase 2/3 readout est. (NCT05141721)
DESCRIPTION:Ipilimumab\, phase 2/3\, Colorectal Cancer.\nStudy: A Study of 
 a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoin
 t Blockade for Patients With Metastatic Colorectal Cancer\nEstimated prima
 ry completion: March 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05141721
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05498792-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270304
DTEND;VALUE=DATE:20270305
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT05498792)
DESCRIPTION:Ipilimumab\, phase 1\, Melanoma.\nStudy: Study of CBL0137 in Co
 mbination With Ipilimumab and Nivolumab Therapy in Melanoma\nEstimated pri
 mary completion: 4 March 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05498792
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05289193-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270311
DTEND;VALUE=DATE:20270312
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05289193)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: CD8+ T Cell Imaging Du
 ring Pre-surgery Immunotherapy in People With Melanoma\nEstimated primary 
 completion: 11 March 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05289193
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03873402-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270311
DTEND;VALUE=DATE:20270312
SUMMARY:Ipilimumab: Phase 3 readout est. (NCT03873402)
DESCRIPTION:Ipilimumab\, phase 3\, Renal Cell Carcinoma.\nStudy: A Study of
  Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants
  With Advanced Kidney Cancer\nEstimated primary completion: 11 March 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT03873402
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03604978-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270319
DTEND;VALUE=DATE:20270320
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT03604978)
DESCRIPTION:Ipilimumab\, phase 1/2.\nStudy: Nivolumab and Multi-fraction St
 ereotactic Radiosurgery With or Without Ipilimumab in Treating Patients Wi
 th Recurrent Grade II-III Meningioma\nEstimated primary completion: 19 Mar
 ch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03604
 978
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03391869-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Ipilimumab: Phase 3 readout est. (NCT03391869)
DESCRIPTION:Ipilimumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Nivo
 lumab and Ipilimumab With or Without Local Consolidation Therapy in Treati
 ng Patients With Stage IV Non-Small Cell Lung Cancer\nEstimated primary co
 mpletion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03391869
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07422779-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Ipilimumab: Phase na readout est. (NCT07422779)
DESCRIPTION:Ipilimumab\, phase na\, Melanoma.\nStudy: Immunotherapy Efficac
 y and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia\n
 Estimated primary completion: 31 March 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07422779
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04730544-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT04730544)
DESCRIPTION:Ipilimumab\, phase 2\, Colorectal Cancer.\nStudy: Two Combinati
 on Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR an
 d / or MSI mCRC.\nEstimated primary completion: April 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04730544
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07560488-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07560488)
DESCRIPTION:Ipilimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Ipilim
 umab N01 Combined With Sintilimab\, Bevacizumab Biosimilar\, and Hepatic A
 rterial Infusion Chemotherapy as Conversion Therapy for Unresectable Inter
 mediate-Advanced Hepatocellular Carcinoma\nEstimated primary completion: A
 pril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075
 60488
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03122522-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03122522)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: A Study to Evaluate Ad
 aptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy\nEstim
 ated primary completion: April 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03122522
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05254184-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT05254184)
DESCRIPTION:Ipilimumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: KRAS
 -Targeted Vaccine With Chemoimmunotherapy\, Nivolumab and Ipilimumab for P
 atients With NSCLC\nEstimated primary completion: 1 April 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05254184
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07751055-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07751055)
DESCRIPTION:Ipilimumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nStu
 dy: Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody
  Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer\nEst
 imated primary completion: 1 April 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07751055
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03097939-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270405
DTEND;VALUE=DATE:20270406
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03097939)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Phase 2 Trial of Ipilimumab and N
 ivolumab in Nasopharyngeal Carcinoma\nEstimated primary completion: 5 Apri
 l 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT030979
 39
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03690986-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270409
DTEND;VALUE=DATE:20270410
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT03690986)
DESCRIPTION:Ipilimumab\, phase 1.\nStudy: VX15/2503 in Combination With Ipi
 limumab or Nivolumab in Patients With Head and Neck Cancer\nEstimated prim
 ary completion: 9 April 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT03690986
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03707808-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270423
DTEND;VALUE=DATE:20270424
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT03707808)
DESCRIPTION:Ipilimumab\, phase 1/2.\nStudy: Intratumoral Injection of Autol
 ogous CD1c (BDCA-1)+ myDC\, AS01B\, and Ipilimumab Plus Systemic Nivolumab
 \nEstimated primary completion: 23 April 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT03707808
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364917-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06364917)
DESCRIPTION:Ipilimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: DISC
 ERN: Dual Versus Single ICB in PDL-1 Negative NSCLC\nEstimated primary com
 pletion: 27 April 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06364917
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03449108-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03449108)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: LN-145 or LN-145-S1 in Treating P
 atients With Relapsed or Refractory Ovarian Cancer\, Triple Negative Breas
 t Cancer (TNBC)\, Anaplastic Thyroid Cancer\, Osteosarcoma\, or Other Bone
  and Soft Tissue Sarcomas\nEstimated primary completion: 30 April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03449108
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05384496-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05384496)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Axitinib and Nivolumab
  for the Treatment of Mucosal Melanoma\nEstimated primary completion: May 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05384496
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07587827-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT07587827)
DESCRIPTION:Ipilimumab\, phase 1\, Colorectal Cancer.\nStudy: Study Evaluat
 ing the Safety Feasibility and Efficacy of ODI-2001 Vaccine\, a Personnali
 zed Immunotherapy in Patients With Metastatic or Locally Advanced Colon Ca
 ncer or Pancreatic Cancer\nEstimated primary completion: 1 May 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07587827
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07919717-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07919717)
DESCRIPTION:Ipilimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: NIVO+I
 PI Neoadjuvant Therapy for Recurrent Resectable HCC\nEstimated primary com
 pletion: 12 May 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07919717
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03918252-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03918252)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Neoadjuvant Immune Checkpoint Blo
 ckade in Resectable Malignant Pleural Mesothelioma\nEstimated primary comp
 letion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ip
 ilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03918252
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03546686-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03546686)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Peri-Operative Immune Checkpoint 
 Inhibition and Cryoablation in Women With Triple-negative Breast Cancer\nE
 stimated primary completion: June 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03546686
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04117087-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT04117087)
DESCRIPTION:Ipilimumab\, phase 1\, Colorectal Cancer.\nStudy: Pooled Mutant
  KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab
  for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and
  Pancreatic Cancer\nEstimated primary completion: 1 June 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04117087
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01896999-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT01896999)
DESCRIPTION:Ipilimumab\, phase 1/2.\nStudy: Brentuximab Vedotin and Nivolum
 ab With or Without Ipilimumab in Treating Patients With Relapsed or Refrac
 tory Hodgkin Lymphoma\nEstimated primary completion: 30 June 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT01896999
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04511013-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT04511013)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: A Study to Compare the
  Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab
  + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases\nEstimated
  primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04511013
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04751370-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT04751370)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Testing Nivolumab and Ipilimumab 
 With Short-Course Radiation in Locally Advanced Rectal Cancer\nEstimated p
 rimary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04751370
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04145115-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT04145115)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: A Study Testing the Effect of Imm
 unotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma Wi
 th Elevated Mutational Burden\nEstimated primary completion: 30 June 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04145115
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05732389-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05732389)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Immunotherapy in Patients With Ea
 rly dMMR Rectal Cancer\nEstimated primary completion: July 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05732389
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03521830-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03521830)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Nivolumab Alone or Plus Relatlima
 b or Ipilimumab for Patients With Locally-Advanced Unresectable or Metasta
 tic Basal Cell Carcinoma\nEstimated primary completion: July 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT03521830
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02496208-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT02496208)
DESCRIPTION:Ipilimumab\, phase 1\, Urothelial Carcinoma.\nStudy: Cabozantin
 ib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients 
 With Metastatic Genitourinary Tumors\nEstimated primary completion: 30 Jul
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT024962
 08
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06377111-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT06377111)
DESCRIPTION:Ipilimumab\, phase 1\, Melanoma.\nStudy: A Study to Test the Be
 nefit of Vitamin B5 in Patients With Melanoma\nEstimated primary completio
 n: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipili
 mumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06377111
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05663775-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05663775)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Prophylactic Mesalamin
 e to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Ni
 vo)\nEstimated primary completion: August 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05663775
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07075120-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT07075120)
DESCRIPTION:Ipilimumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: Ipilim
 umab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer\nEs
 timated primary completion: 1 August 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07075120
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03502733-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT03502733)
DESCRIPTION:Ipilimumab\, phase 1.\nStudy: Testing the Combination of Copanl
 isib\, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymph
 oma\nEstimated primary completion: 1 August 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03502733
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05896839-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270802
DTEND;VALUE=DATE:20270803
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT05896839)
DESCRIPTION:Ipilimumab\, phase 1/2\, Melanoma.\nStudy: Immunotherapy in Com
 bination With Prednisone and Sirolimus for Kidney Transplant Recipients Wi
 th Unresectable or Metastatic Skin Cancer\nEstimated primary completion: 2
  August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05896839
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01688492-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT01688492)
DESCRIPTION:Ipilimumab\, phase 1/2.\nStudy: Combining Ipilimumab With Abira
 terone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Pa
 tients With Progressive Metastatic Castration-resistant Prostate Cancer\nE
 stimated primary completion: September 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT01688492
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: The Drug Rediscovery Protocol (DR
 UP Trial)\nEstimated primary completion: September 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06594991-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06594991)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: A Study of Fianlimab\,
  Cemiplimab\, and Ipilimumab in People With Melanoma\nEstimated primary co
 mpletion: September 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06594991
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03233139-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT03233139)
DESCRIPTION:Ipilimumab\, phase 1.\nStudy: Safety and Pharmacokinetics of Ce
 miplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Ja
 panese Adult Patients With Advanced Malignancies\nEstimated primary comple
 tion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03233139
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04697576-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT04697576)
DESCRIPTION:Ipilimumab\, phase 1\, Melanoma.\nStudy: Intralesional Influenz
 a Vaccine for the Treatment of Stage I-IV Melanoma\nEstimated primary comp
 letion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04697576
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02530463-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT02530463)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Nivolumab and/or Ipilimumab With 
 or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome\
 nEstimated primary completion: 30 September 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT02530463
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05361720-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05361720)
DESCRIPTION:Ipilimumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Genetic Te
 sting to Select Therapy for the Treatment of Advanced or Metastatic Kidney
  Cancer\, OPTIC RCC Study\nEstimated primary completion: 1 October 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05361720
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05012254-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05012254)
DESCRIPTION:Ipilimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Nivo
 lumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Can
 cer With Brain Metastases\nEstimated primary completion: 15 October 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05012254
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227012-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20271018
DTEND;VALUE=DATE:20271019
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT07227012)
DESCRIPTION:Ipilimumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Symb
 iotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a
  Single Treatment and Combination Treatment in Adult Participants With a L
 iver Cancer Called Hepatocellular Carcinoma\, That is Too Advanced to be R
 emoved by Surgery and May Have Spread to Other Parts of the Body.\nEstimat
 ed primary completion: 18 October 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07227012
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03307616-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03307616)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Nivolumab With and Without Ipilim
 umab and Radiation Therapy in Treating Patients With Recurrent or Resectab
 le Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Be
 fore Surgery\nEstimated primary completion: 31 October 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03307616
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03406247-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03406247)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Adjuvant Immunotherapy After Salv
 age Surgery in Head and Neck Squamous Cell Carcinoma\nEstimated primary co
 mpletion: November 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03406247
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227415-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20271102
DTEND;VALUE=DATE:20271103
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT07227415)
DESCRIPTION:Ipilimumab\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Symbioti
 c-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alon
 e and in Combination With Other Anticancer Therapies in Adults With Locall
 y Advanced or Metastatic Renal Cell Cancer\nEstimated primary completion: 
 2 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipil
 imumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07227415
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07401875-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT07401875)
DESCRIPTION:Ipilimumab\, phase 1.\nStudy: A Phase 1b Study of HC-7366\, an 
 Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)\nEstimated prim
 ary completion: 30 November 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07401875
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07506109-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07506109)
DESCRIPTION:Ipilimumab\, phase 2\, Colorectal Cancer.\nStudy: A Phase II St
 udy of Sintilimab Combined With Ipilimumab N01\, Cetuximab and Dabrafenib 
 in Patients With Microsatellite-Stable\, BRAF V600E-Mutated Metastatic Col
 orectal Cancer\nEstimated primary completion: December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07506109
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230613-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07230613)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Neo-adjuvant Immunothe
 rapy in Patients With Localized Melanoma\nEstimated primary completion: De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7230613
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07364474-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ipilimumab: Phase na readout est. (NCT07364474)
DESCRIPTION:Ipilimumab\, phase na\, Melanoma.\nStudy: Immune Response to Pe
 rcutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic
  to the Liver\nEstimated primary completion: December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07364474
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02950766-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT02950766)
DESCRIPTION:Ipilimumab\, phase 1\, Renal Cell Carcinoma.\nStudy: NeoVax Plu
 s Ipilimumab in Renal Cell Carcinoma\nEstimated primary completion: 31 Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02
 950766
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04013542-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT04013542)
DESCRIPTION:Ipilimumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Ipil
 imumab and Nivolumab in Combination With Radiation Therapy in Treating Pat
 ients With Stage 2-3 Non-small Lung Cancer\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipi
 limumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04013542
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06362369-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT06362369)
DESCRIPTION:Ipilimumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed
  by Nivolumab Monotherapy\nEstimated primary completion: 31 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06362369
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02696993-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT02696993)
DESCRIPTION:Ipilimumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Ni
 volumab and Radiation Therapy With or Without Ipilimumab in Treating Patie
 nts With Brain Metastases From Non-small Cell Lung Cancer\nEstimated prima
 ry completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT02696993
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04566380-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT04566380)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: ONO-4538 Phase II Rollover Study 
 (ONO-4538-98)\nEstimated primary completion: 31 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04566380
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02693535-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT02693535)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: TAPUR: Testing the Use of Food an
 d Drug Administration (FDA) Approved Drugs That Target a Specific Abnormal
 ity in a Tumor Gene in People With Advanced Stage Cancer\nEstimated primar
 y completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT02693535
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05048212-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05048212)
DESCRIPTION:Ipilimumab\, phase 2\, Renal Cell Carcinoma.\nStudy: A Phase II
  Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untr
 eated Renal Cell Carcinoma Brain Metastases\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ip
 ilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05048212
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564570-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ipilimumab: Phase na readout est. (NCT07564570)
DESCRIPTION:Ipilimumab\, phase na\, Melanoma.\nStudy: Physical Activity Dir
 ectly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma\nEstimat
 ed primary completion: 31 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07564570
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05779423-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05779423)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Cryoablation+Ipilimuma
 b+Nivolumab in Melanoma\nEstimated primary completion: 1 January 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05779423
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06163820-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT06163820)
DESCRIPTION:Ipilimumab\, phase 1/2\, Melanoma.\nStudy: Bevacizumab and ICIs
  + hSRT in Symptomatic Melanoma Brain Metastases\nEstimated primary comple
 tion: 30 January 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06163820
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06999980-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06999980)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Neo IRENIE (NEOadjuvan
 t Ipilimumab\, RElatlimab\, NIvolumab Evaluation)\nEstimated primary compl
 etion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ip
 ilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06999980
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03793166-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Ipilimumab: Phase 3 readout est. (NCT03793166)
DESCRIPTION:Ipilimumab\, phase 3\, Renal Cell Carcinoma.\nStudy: Immunother
 apy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With 
 Cabozantinib for Patients With Advanced Kidney Cancer\, The PDIGREE Study\
 nEstimated primary completion: 1 March 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03793166
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05428007-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280317
DTEND;VALUE=DATE:20280318
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05428007)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Interleukin-6 Receptor
  Inhibitor Sarilumab in Combination With Ipilimumab\, Nivolumab and Relatl
 imab in Patients With Unresectable Stage III or Stage IV Melanoma\nEstimat
 ed primary completion: 17 March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05428007
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07487662-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280319
DTEND;VALUE=DATE:20280320
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07487662)
DESCRIPTION:Ipilimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: TACE o
 r Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Ther
 apy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurre
 nce Risk\nEstimated primary completion: 19 March 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07487662
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03816345-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT03816345)
DESCRIPTION:Ipilimumab\, phase 1.\nStudy: Testing an Immunotherapy Anti-can
 cer Drug\, Nivolumab\, for Advanced Cancers in Patients With Autoimmune Di
 sorders\, AIM-NIVO\nEstimated primary completion: 30 March 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT03816345
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02703623-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT02703623)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Abiraterone Acetate\, Prednisone\
 , and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplati
 n in Treating Patients With Metastatic Castration-Resistant Prostate Cance
 r\nEstimated primary completion: 31 March 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT02703623
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05836571-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05836571)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Testing Ipilimumab and Nivolumab 
 Combination With or Without Cabozantinib in People >= 18 Years Old With Ad
 vanced Soft Tissue Sarcoma\nEstimated primary completion: 15 May 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05836571
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07511036-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280524
DTEND;VALUE=DATE:20280525
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07511036)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: PROSECCO: A Phase 2\, 
 Single Arm\, Neoadjuvant Study Evaluating Combination Cemiplimab\, Fianlim
 ab\, And Ipilimumab In Patients With Surgically Resectable Melanoma\nEstim
 ated primary completion: 24 May 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07511036
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747845-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06747845)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Maintenance Niraparib Plus Ipilim
 umab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease H
 as Not Progressed on Platinum-Based Chemotherapy\nEstimated primary comple
 tion: June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipil
 imumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06747845
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07654530-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07654530)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Sintilimab Combined With Ipilimum
 ab (N01) Plus AG as First-line Therapy for uBTC.\nEstimated primary comple
 tion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/i
 pilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07654530
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07893340-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07893340)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: First-line Treatment With Dual Im
 munotherapy Combined With Anti-angiogenesis for Unresectable Advanced Mali
 gnant Peritoneal Mesothelioma\nEstimated primary completion: 30 June 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07893340
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07615881-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT07615881)
DESCRIPTION:Ipilimumab\, phase 1/2\, Melanoma.\nStudy: Comparing Intravenou
 s or Intradermal Administration of Anti-CTLA-4 in Combination With Anti-PD
 1 Treatment in Patients With Melanoma\nEstimated primary completion: July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07615881
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06031233-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Ipilimumab: Phase 4 readout est. (NCT06031233)
DESCRIPTION:Ipilimumab\, phase 4.\nStudy: Evaluating the Safety of Shortene
 d Infusion Times for dIfferent Oncological Immunotherapie\nEstimated prima
 ry completion: July 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06031233
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07128680-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20280825
DTEND;VALUE=DATE:20280826
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT07128680)
DESCRIPTION:Ipilimumab\, phase 1\, Renal Cell Carcinoma.\nStudy: Immunother
 apy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Prod
 uct (EXL01) for the Treatment of Metastatic Renal Cell Cancer\nEstimated p
 rimary completion: 25 August 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07128680
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07233668-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Ipilimumab: Phase na readout est. (NCT07233668)
DESCRIPTION:Ipilimumab\, phase na\, Renal Cell Carcinoma.\nStudy: Immediate
  Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mR
 CC\nEstimated primary completion: 1 October 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07233668
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07878221-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07878221)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: A Phase II Study of Ipilimumab N0
 1 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction 
 Cancer\nEstimated primary completion: 20 October 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07878221
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06295159-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06295159)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Neoadjuvant and Adjuva
 nt Anti-PD1 or Combinations for Locoregionally Advanced Melanoma\nEstimate
 d primary completion: November 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06295159
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05501054-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT05501054)
DESCRIPTION:Ipilimumab\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Phase 1b
 /2 Trial of Ipilimumab\, Nivolumab\, and Ciforadenant (Adenosine A2a Recep
 tor Antagonist) in First-line Advanced Renal Cell Carcinoma.\nEstimated pr
 imary completion: 1 November 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05501054
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04605146-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20281105
DTEND;VALUE=DATE:20281106
SUMMARY:Ipilimumab: Phase na readout est. (NCT04605146)
DESCRIPTION:Ipilimumab\, phase na\, Melanoma.\nStudy: Impact of Telemonitor
 ing for the Management of Side Effects in Patients with Melanoma\, Lung or
  Renal Cancer\, Treated with Immunotherapy Combination of Nivolumab and Ip
 ilimumab or Adjuvant Nivolumab Monotherapy\nEstimated primary completion: 
 5 November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipil
 imumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04605146
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06941857-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06941857)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: NC410 and FOLFIRINOX in Combinati
 on With Nivolumab With or Without Ipilimumab in Patients With Untreated Me
 tastatic Pancreatic Cancer\nEstimated primary completion: December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06941857
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06708949-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06708949)
DESCRIPTION:Ipilimumab\, phase 2\, Renal Cell Carcinoma.\nStudy: A Randomiz
 ed Phase 2 Trial of Nivolumab\, Relatlimab Plus Ipilimumab vs. Nivolumab P
 lus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)\nEstimate
 d primary completion: 15 December 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06708949
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492408-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06492408)
DESCRIPTION:Ipilimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Neoadj
 uvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.\nEsti
 mated primary completion: 30 December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06492408
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492421-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06492421)
DESCRIPTION:Ipilimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant Intra-tumor Double Immunotherapy for Lung Cancer.\nEstimated prima
 ry completion: 30 December 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06492421
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07638631-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07638631)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Ipilimumab (N01) Plus Sintilimab 
 and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced 
 Gastric Cancer\nEstimated primary completion: 31 December 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07638631
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07611825-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07611825)
DESCRIPTION:Ipilimumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Gut Microb
 iota Modulation for Immunotherapy Resensitization in Advanced Renal Cell C
 arcinoma\nEstimated primary completion: 31 December 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07611825
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07917767-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07917767)
DESCRIPTION:Ipilimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Pr
 ospective Cohort Study of PD-1 Monoclonal Antibody Combined With Ipilimuma
 b N01 and Chemotherapy in Perioperative Treatment of Resectable Non-small 
 Cell Lung Cancer\nEstimated primary completion: 31 December 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07917767
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05536141-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT05536141)
DESCRIPTION:Ipilimumab\, phase 1\, Renal Cell Carcinoma.\nStudy: A Phase 1 
 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcino
 ma and Other Solid Tumors\nEstimated primary completion: March 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05536141
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07740941-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07740941)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: NeoAdjuvant\, Spare-Ad
 juvant (NASA) in Stage IIIB-IV (M1a) Melanoma\nEstimated primary completio
 n: March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilim
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07740941
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04248569-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT04248569)
DESCRIPTION:Ipilimumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: DNAJB1
 -PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimum
 ab for Patients With Fibrolamellar Hepatocellular Carcinoma\nEstimated pri
 mary completion: 1 March 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04248569
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07532902-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT07532902)
DESCRIPTION:Ipilimumab\, phase 1\, Urothelial Carcinoma.\nStudy: A Study of
  BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Canc
 er\nEstimated primary completion: April 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07532902
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07877194-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20290412
DTEND;VALUE=DATE:20290413
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07877194)
DESCRIPTION:Ipilimumab\, phase 2\, Renal Cell Carcinoma.\nStudy: A Clinical
  Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Ad
 vanced Renal Cancer\nEstimated primary completion: 12 April 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07877194
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07504796-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07504796)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: ctDNA-guided Addition 
 of Ipilimumab to Patients Receiving Nivolumab and Relatlimab\nEstimated pr
 imary completion: May 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07504796
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07501117-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT07501117)
DESCRIPTION:Ipilimumab\, phase 1\, Melanoma.\nStudy: Neoadjuvant Immunother
 apy for Patients With High-risk Eye Melanoma\nEstimated primary completion
 : 1 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilim
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07501117
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06240143-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT06240143)
DESCRIPTION:Ipilimumab\, phase 1/2\, Melanoma.\nStudy: Intradermal Ipilimum
 ab and Nivolumab in High Risk Stage II Melanoma\nEstimated primary complet
 ion: July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipili
 mumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06240143
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683221-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20290715
DTEND;VALUE=DATE:20290716
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07683221)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: SBRT Followed by Ipilimumab N01\,
  Sintilimab\, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreat
 ic Cancer\nEstimated primary completion: 15 July 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07683221
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03899155-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20290825
DTEND;VALUE=DATE:20290826
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03899155)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Pan Tumor Rollover Study\nEstimat
 ed primary completion: 25 August 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03899155
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07563738-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT07563738)
DESCRIPTION:Ipilimumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 2-part Phase 1/2 Open-label Trial on ODM-212\nEstimated primary completion
 : September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipi
 limumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07563738
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07879586-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Ipilimumab: Phase 2/3 readout est. (NCT07879586)
DESCRIPTION:Ipilimumab\, phase 2/3.\nStudy: Neoadjuvant Chemoradiotherapy P
 lus PD-1 Blockade ± CTLA-4 Blockade for High-Risk Locally Advanced Rectal
  Cancer (pMMR/MSS): A National Multicenter\, Prospective\, Randomized Cont
 rolled Trial\nEstimated primary completion: 1 October 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07879586
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07879599-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Ipilimumab: Phase 2/3 readout est. (NCT07879599)
DESCRIPTION:Ipilimumab\, phase 2/3.\nStudy: Neoadjuvant Chemoradiotherapy P
 lus PD-1 Blockade ± CTLA-4 Blockade for Low/Intermediate-Risk Locally Adv
 anced Rectal Cancer (pMMR/MSS): A National Multicenter\, Prospective\, Ran
 domized Controlled Trial\nEstimated primary completion: 1 October 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07879599
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07291076-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20291015
DTEND;VALUE=DATE:20291016
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT07291076)
DESCRIPTION:Ipilimumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: A St
 udy to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combi
 nation With Ipilimumab in Participants With First-Line Advanced or Unresec
 table Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)\nEstimated primary 
 completion: 15 October 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07291076
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05187338-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20291030
DTEND;VALUE=DATE:20291031
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT05187338)
DESCRIPTION:Ipilimumab\, phase 1/2\, Colorectal Cancer.\nStudy: Triplex Che
 ckpoint Inhibitors Therapy for Advanced Solid Tumors\nEstimated primary co
 mpletion: 30 October 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05187338
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07838974-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT07838974)
DESCRIPTION:Ipilimumab\, phase 1\, Melanoma.\nStudy: Adding Anakinra and To
 cilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patien
 ts 50 Years of Age or Older\nEstimated primary completion: 1 November 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07838974
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04665206-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20291102
DTEND;VALUE=DATE:20291103
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT04665206)
DESCRIPTION:Ipilimumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: St
 udy to Evaluate VT3989 in Patients With Metastatic Solid Tumors\nEstimated
  primary completion: 2 November 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04665206
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07293351-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20291128
DTEND;VALUE=DATE:20291129
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT07293351)
DESCRIPTION:Ipilimumab\, phase 1/2\, Renal Cell Carcinoma.\nStudy: A Study 
 to Evaluate the Safety\, Tolerability\, and Efficacy of Pumitamig Alone or
  in Combination With Other Agents in Participants With Advanced Renal Cell
  Carcinoma (RCC) (ROSETTA RCC-208)\nEstimated primary completion: 28 Novem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0729
 3351
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07188896-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07188896)
DESCRIPTION:Ipilimumab\, phase 2\, Renal Cell Carcinoma.\nStudy: A Randomiz
 ed Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Niv
 olumab in First-line Advanced Renal Cell Carcinoma (RCC)\nEstimated primar
 y completion: 30 November 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07188896
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07715565-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07715565)
DESCRIPTION:Ipilimumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Ipilimumab
  N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Adva
 nced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective\, M
 ulticenter\, Single-Arm\, Phase II Clinical Trial\nEstimated primary compl
 etion: December 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07715565
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07756190-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07756190)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Radscopal Radiotherapy Plus Immun
 otherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metasta
 tic Nasopharyngeal Cancer: A Single-Center\, Open-Label\, Phase II Study\n
 Estimated primary completion: 30 December 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07756190
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06581406-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Ipilimumab: Phase 2/3 readout est. (NCT06581406)
DESCRIPTION:Ipilimumab\, phase 2/3\, Melanoma.\nStudy: A Randomized\, Phase
  2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination Wi
 th Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Met
 astatic Uveal Melanoma\nEstimated primary completion: January 2030. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06581406
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06926790-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06926790)
DESCRIPTION:Ipilimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)\nEstimate
 d primary completion: 31 March 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06926790
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07195682-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20300503
DTEND;VALUE=DATE:20300504
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT07195682)
DESCRIPTION:Ipilimumab\, phase 1\, Renal Cell Carcinoma.\nStudy: A First-in
 -Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal 
 Cell Carcinoma (ccRCC)\nEstimated primary completion: 3 May 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07195682
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06889493-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT06889493)
DESCRIPTION:Ipilimumab\, phase 1.\nStudy: SVV-001 With Nivolumab and Ipilim
 umab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC
 ) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)\nEstimated
  primary completion: 1 June 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06889493
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06683755-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20300816
DTEND;VALUE=DATE:20300817
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT06683755)
DESCRIPTION:Ipilimumab\, phase 1/2\, Melanoma.\nStudy: Phase I/IIa Dose Fin
 ding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in Fi
 rst Line Therapy of Metastatic Melanoma (TRINITY)\nEstimated primary compl
 etion: 16 August 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06683755
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762703-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT07762703)
DESCRIPTION:Ipilimumab\, phase 1/2.\nStudy: Combination Immunotherapy Treat
 ment for Locally Advanced Unresectable or Metastatic\, PD-L1 Negative (CPS
 <10)\, gBRCA Negative\, Triple Negative Breast Cancer Including BreakVax I
 mmunoTreatment (Designed and Manufactured Per Patient)\, Chemotherapy and 
 Anti PD-1 Therapy\nEstimated primary completion: September 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07762703
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762716-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT07762716)
DESCRIPTION:Ipilimumab\, phase 1/2.\nStudy: Combination Immunotherapy Treat
 ment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Man
 ufactured Per Patient)\, Chemotherapy and Anti PD-1 Therapy\nEstimated pri
 mary completion: September 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07762716
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07430202-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT07430202)
DESCRIPTION:Ipilimumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: A DNAJ
 B1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist
  DRP-104\, Nivolumab\, and Ipilimumab in Patients With Advanced Stage Fibr
 olamellar Carcinoma (FLC)\nEstimated primary completion: October 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07430202
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07930182-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20301021
DTEND;VALUE=DATE:20301022
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07930182)
DESCRIPTION:Ipilimumab\, phase 2\, Melanoma.\nStudy: Adjuvant/Neoadjuvant I
 mmunotherapy in Melanoma Based on Serial Plasma ctDNA Monitoring\nEstimate
 d primary completion: 21 October 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07930182
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04929041-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20301212
DTEND;VALUE=DATE:20301213
SUMMARY:Ipilimumab: Phase 2/3 readout est. (NCT04929041)
DESCRIPTION:Ipilimumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: Te
 sting the Addition of Radiation Therapy to the Usual Treatment (Immunother
 apy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung C
 ancer Patients Who Are PD-L1 Negative\nEstimated primary completion: 12 De
 cember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4929041
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03138161-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT03138161)
DESCRIPTION:Ipilimumab\, phase 1/2.\nStudy: SAINT:Trabectedin\, Ipilimumab 
 and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma\nEstimat
 ed primary completion: 31 December 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03138161
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03815890-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20310101
DTEND;VALUE=DATE:20310102
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03815890)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Pre-operative Trial for Breast Ca
 ncer With Nivolumab in Combination With Novel IO\nEstimated primary comple
 tion: 1 January 2031. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT03815890
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06866262-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20310801
DTEND;VALUE=DATE:20310802
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT06866262)
DESCRIPTION:Ipilimumab\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Inulin G
 el in Combination With Ipilimumab and Nivolumab for the Treatment of Metas
 tatic or Locally Advanced Kidney Cell Cancer\, ICON Trial\nEstimated prima
 ry completion: 1 August 2031. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06866262
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07689175-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07689175)
DESCRIPTION:Ipilimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Adapti
 ve Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma\nEs
 timated primary completion: 31 October 2031. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07689175
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07338981-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Ipilimumab: Phase 3 readout est. (NCT07338981)
DESCRIPTION:Ipilimumab\, phase 3.\nStudy: The Impact of Time-of-day-Depende
 nt Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall
  Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter\,
  Randomized Controlled Trial.\nEstimated primary completion: December 2031
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07338981
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444619-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Ipilimumab: Phase 1 readout est. (NCT07444619)
DESCRIPTION:Ipilimumab\, phase 1.\nStudy: A Phase I Study of Pazopanib in C
 ombination With Trabectedin\, Ipilimumab and Nivolumab (TraPIN) in Pediatr
 ic and Young Adult Patients With Recurrent Soft Tissue Sarcomas\nEstimated
  primary completion: 31 December 2031. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07444619
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07403877-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07403877)
DESCRIPTION:Ipilimumab\, phase 2\, Colorectal Cancer.\nStudy: Neoadjuvant I
 mmunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Can
 cer\nEstimated primary completion: 31 December 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07403877
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643623-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Ipilimumab: Phase 2/3 readout est. (NCT07643623)
DESCRIPTION:Ipilimumab\, phase 2/3.\nStudy: Neoadjuvant and Adjuvant Therap
 y Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimu
 mab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma\nEs
 timated primary completion: 31 December 2031. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07643623
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05533697-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20320218
DTEND;VALUE=DATE:20320219
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT05533697)
DESCRIPTION:Ipilimumab\, phase 1/2.\nStudy: Study of mRNA-4359 Administered
  Alone and in Combination With Immune Checkpoint Blockade in Participants 
 With Advanced Solid Tumors\nEstimated primary completion: 18 February 2032
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05533697
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03026140-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20320301
DTEND;VALUE=DATE:20320302
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT03026140)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Neoadjuvant Immune Checkpoint Inh
 ibition and Novel IO Combinations in Early-stage Colon Cancer\nEstimated p
 rimary completion: 1 March 2032. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT03026140
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06794775-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20320415
DTEND;VALUE=DATE:20320416
SUMMARY:Ipilimumab: Phase 3 readout est. (NCT06794775)
DESCRIPTION:Ipilimumab\, phase 3\, Melanoma.\nStudy: SWE-NEO: Swedish NeoAd
 juvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable
  Stage III Melanoma\nEstimated primary completion: 15 April 2032. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06794775
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364631-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20320505
DTEND;VALUE=DATE:20320506
SUMMARY:Ipilimumab: Phase 3 readout est. (NCT06364631)
DESCRIPTION:Ipilimumab\, phase 3.\nStudy: CARE1 Pragmatic Clinical Trial\nE
 stimated primary completion: 5 May 2032. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06364631
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05112601-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20320730
DTEND;VALUE=DATE:20320731
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05112601)
DESCRIPTION:Ipilimumab\, phase 2.\nStudy: Testing Nivolumab With or Without
  Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometri
 al Carcinoma\nEstimated primary completion: 30 July 2032. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05112601
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07355205-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20320731
DTEND;VALUE=DATE:20320801
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT07355205)
DESCRIPTION:Ipilimumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Fi
 rst-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803
 ) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer\nEstim
 ated primary completion: 31 July 2032. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07355205
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02339571-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Ipilimumab: Phase 2/3 readout est. (NCT02339571)
DESCRIPTION:Ipilimumab\, phase 2/3\, Melanoma.\nStudy: A Phase II/III Trial
  of Nivolumab\, Ipilimumab\, and GM-CSF in Patients With Advanced Melanoma
 \nEstimated primary completion: 30 June 2033. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT02339571
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07510334-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20330801
DTEND;VALUE=DATE:20330802
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07510334)
DESCRIPTION:Ipilimumab\, phase 2\, Renal Cell Carcinoma.\nStudy: VSV-IFNβ-
 NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metasta
 tic Clear Cell Renal Cell Carcinoma\nEstimated primary completion: 1 Augus
 t 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075103
 34
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770100-2009@assetmemo.bio
DTSTAMP:20261121T004055Z
DTSTART;VALUE=DATE:20400228
DTEND;VALUE=DATE:20400229
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07770100)
DESCRIPTION:Ipilimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Conc
 urrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation
  Therapy (SBRT) for Stage IV Cancers (COINSSS IV)\nEstimated primary compl
 etion: 28 February 2040. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07770100
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
